Vir Biotechnology: Fairly Valued After Phase 3 Success?

What happened: A Seeking Alpha analyst reiterated a Buy on Vir Biotechnology ($VIR) after Phase 3 ECLIPSE 1 results for its Hepatitis Delta therapy and a new Gilead partnership. Key numbers: 44% primary endpoint success; 79% undetectable virus rates; $991.3 million in cash; $5.79 per-share cash floor; funding into H2 2028; risk-adjusted fair value $15.48; prior $1.7 Why it matters: The analyst views the cash position and funding runway as limiting downside risk, and sees the $15.48 risk-adjusted fair value as above current trading levels even under conservative market capture assumptions.

A Seeking Alpha analyst reiterated a Buy on Vir Biotechnology ($VIR) after Phase 3 ECLIPSE 1 results for its Hepatitis Delta therapy and a new Gilead partnership.

The analyst views the cash position and funding runway as limiting downside risk, and sees the $15.48 risk-adjusted fair value as above current trading levels even under conservative market capture assumptions.